Invest in

Drug-Patent Cliffs

13.4%
5.3%
0.0%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
13.4%
5.3%
0.0%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 7.7%
20.0% Taro Pharmaceutical Industries Ltd. TARO 22.3%
19.2% Dr. Reddy's Laboratories Ltd RDY 12.9%
13.4% Mylan N.V. MYL 24.0%
11.5% Akorn Inc. AKRX 17.6%
10.5% The Medicines Company MDCO 45.7%
8.8% Abbott Laboratories ABT 2.8%
4.8% Impax Laboratories Inc. IPXL 63.3%
4.1% Lannett Co Inc LCI 22.3%
3.0% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 44.5%
2.7% Mallinckrodt plc MNK 30.6%
1.1% Cambrex Corporation CBM 25.7%
0.9% Endo International PLC ENDP 67.1%

Quotes delayed 15 mins. Currently Apr 24, 2017 9:06:17 AM. Fields are marked with -- when data is unavailable.